Eton Pharmaceuticals, Inc. (ETON)

Market Cap	349.16M
Revenue (ttm)	39.01M
Net Income (ttm)	-3.82M
Shares Out	26.82M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	32.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,917
Open	13.52
Previous Close	13.51
Day's Range	12.83 - 13.64
52-Week Range	3.03 - 18.41
Beta	1.37
Analysts	Strong Buy
Price Target	27.67 (+112.52%)
Earnings Date	Mar 18, 2025

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortison...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON
• Website: https://www.etonpharma.com

Financial Performance

In 2024, Eton Pharmaceuticals's revenue was $39.01 million, an increase of 23.29% compared to the previous year's $31.64 million. Losses were -$3.82 million, 308.4% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $27.67, which is an increase of 112.52% from the latest price.

Price Target

$27.67

(112.52% upside)

Analyst Consensus: Strong Buy